Robeco Institutional Asset Management B.V. Has $158.03 Million Stock Holdings in McKesson Co. (NYSE:MCK)

Robeco Institutional Asset Management B.V. lowered its holdings in shares of McKesson Co. (NYSE:MCK) by 5.6% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 319,634 shares of the company’s stock after selling 18,942 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.25% of McKesson worth $158,033,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Van ECK Associates Corp raised its stake in McKesson by 30.9% during the third quarter. Van ECK Associates Corp now owns 81,957 shares of the company’s stock worth $41,123,000 after acquiring an additional 19,330 shares in the last quarter. Campbell Capital Management Inc. increased its position in McKesson by 120.1% during the 3rd quarter. Campbell Capital Management Inc. now owns 9,860 shares of the company’s stock worth $4,875,000 after purchasing an additional 5,380 shares in the last quarter. Pure Financial Advisors LLC lifted its stake in McKesson by 3.2% in the 3rd quarter. Pure Financial Advisors LLC now owns 767 shares of the company’s stock valued at $379,000 after purchasing an additional 24 shares during the last quarter. BluePath Capital Management LLC boosted its position in McKesson by 14.2% in the third quarter. BluePath Capital Management LLC now owns 1,379 shares of the company’s stock valued at $682,000 after buying an additional 171 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its stake in shares of McKesson by 17.0% during the third quarter. Chicago Partners Investment Group LLC now owns 682 shares of the company’s stock worth $342,000 after buying an additional 99 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Brian S. Tyler sold 3,753 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $561.10, for a total value of $2,105,808.30. Following the completion of the sale, the chief executive officer now directly owns 78,586 shares in the company, valued at $44,094,604.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.11% of the company’s stock.

McKesson Trading Up 5.1 %

Shares of McKesson stock opened at $526.34 on Monday. The company has a market cap of $68.26 billion, a P/E ratio of 23.54, a PEG ratio of 1.17 and a beta of 0.44. The business has a 50-day moving average price of $512.00 and a two-hundred day moving average price of $550.57. McKesson Co. has a 1-year low of $431.35 and a 1-year high of $637.51.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 7th. The company reported $7.88 earnings per share for the quarter, topping analysts’ consensus estimates of $7.21 by $0.67. The business had revenue of $79.28 billion during the quarter, compared to the consensus estimate of $82.53 billion. McKesson had a negative return on equity of 242.57% and a net margin of 0.94%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the company posted $7.27 earnings per share. Equities research analysts forecast that McKesson Co. will post 31.92 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend is Monday, December 2nd. McKesson’s payout ratio is 12.70%.

Analysts Set New Price Targets

MCK has been the topic of several recent research reports. Mizuho boosted their price objective on McKesson from $540.00 to $570.00 and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Barclays boosted their price target on McKesson from $596.00 to $616.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of McKesson from $623.00 to $579.00 and set a “buy” rating for the company in a report on Wednesday, September 25th. Leerink Partners reduced their target price on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Finally, Wells Fargo & Company decreased their price target on shares of McKesson from $576.00 to $535.00 and set an “equal weight” rating for the company in a research report on Friday, September 13th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, McKesson has a consensus rating of “Moderate Buy” and an average target price of $610.86.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.